enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q3 2024 vs. Q2 2024
How the institutions holding enGene Therapeutics Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 30 | 30 | 0 |
| Shares | 32.6M | 34.3M | +1.68M (+5.2%) |
| Value | $307.1M | $227.7M | −$79.4M (−25.9%) |
New holders (6)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kynam Capital Management, LP | 1,736,227 | $11.5M | 0.89% |
| Sectoral Asset Management Inc | 94,219 | $621.8K | 0.37% |
| Two Sigma Investments, LP | 39,621 | $261.5K | 0.00% |
| Northern Trust Corp | 34,416 | $227.1K | 0.00% |
| Cubist Systematic Strategies, LLC | 13,262 | $87.5K | 0.00% |
| Wolverine Asset Management LLC | 5,574 | $36.8K | 0.00% |
Sold out (6)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Perceptive Advisors LLC | 800,000 | $7.54M |
| Citadel Advisors LLC | 613,292 | $5.78M |
| Silverarc Capital Management, LLC | 263,841 | $2.49M |
| Verition Fund Management LLC | 14,843 | $140.0K |
| Ameriprise Financial Inc | 12,524 | $118.1K |
| UBS Group AG | 3,370 | $31.8K |